


PRODUCT INFORMATION



Losartan Carboxylic Acid

Item No. 15957

CAS Registry No.: 124750-92-1
Formal Name: 2-butyl-4-chloro-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid
Synonyms: E-3174, EXP-3174
MF: C₂₂H₂₁ClN₆O₂
FW: 436.9
Purity: ≥98%
UV/Vis.: λ_{max}: 247 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Losartan carboxylic acid is supplied as a crystalline solid. A stock solution may be made by dissolving the losartan carboxylic acid in the solvent of choice, which should be purged with an inert gas. Losartan carboxylic acid is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of losartan carboxylic acid in these solvents is approximately 30 mg/ml.

Losartan carboxylic acid is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, losartan carboxylic acid should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Losartan carboxylic acid has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Losartan carboxylic acid is a physiologically active metabolite of losartan (Item No. 10006594), produced by cytochrome P450 isoforms in the liver.¹ Like the parent compound, losartan carboxylic acid is a potent AT₁ antagonist (K_is = 0.57 and 0.67 nM for rat and human forms, respectively), producing a depressor response and vasodilatation.²⁻⁴ When administered intravenously, losartan carboxylic acid is more potent and has a longer duration of action than losartan.⁴ However, the metabolite has very low oral bioavailability.⁴ Losartan, but not its metabolite, inhibits platelet aggregation *in vitro*.⁵

References

1. Yasar, U., Tybring, G., Hidestrand, M., *et al.* Role of CYP2C9 polymorphism in losartan oxidation. *Drug Metabolism and Disposition* **29**(7), 1051-1056 (2001).
2. Inada, Y., Nakane, T., and Chiba, S. Binding of KRH-594, an antagonist of the angiotensin II type 1 receptor, to cloned human and rat angiotensin II receptors. *Fundam. Clin. Pharmacol.* **16**(4), 317-323 (2002).
3. Widdop, R.E., Gardiner, S.M., Kemp, P.A., *et al.* Comparison of the regional haemodynamic effects of the AT₁-receptor antagonists, losartan and EXP 3174, in water-deprived Brattleboro rats. *British Journal of Pharmacology* **108**(3), 684-688 (1993).
4. Burnier, M. Angiotensin II type 1 receptor blockers. *Circulation* **103**(6), 904-912 (2001).
5. Munger, M.A. Use of angiotensin receptor blockers in cardiovascular protection: Current evidence and future directions. *PT* **36**(1), 22-40 (2011).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/07/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM